ClinicalTrials.gov
ClinicalTrials.gov Menu

Neoadjuvant Paclitaxel Versus BIBF 1120 Priming Followed by BIBF 1120 Plus Paclitaxel in Early HER-2 Negative Breast Cancer With Proteomic and Dynamic Imaging Correlates

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01484080
Recruitment Status : Completed
First Posted : December 2, 2011
Last Update Posted : April 16, 2015
Sponsor:
Collaborators:
Hospital Universitario de Fuenlabrada
M.D. Anderson Cancer Center
Hospital Universitari de Bellvitge
Grupo Espanol de Investigacion del Cancer de Mama
Information provided by (Responsible Party):
Centro Nacional de Investigaciones Oncologicas CARLOS III

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : November 2013
  Actual Study Completion Date : April 2014